---
title: "CIGU TECHNOLOGY: The cumulative deviation value of the closing drop on the 30th is 70%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259498349.md"
description: "CIGU TECHNOLOGY announced that the company's stock has experienced a cumulative decline of 70% in closing prices over the last 30 trading days, triggering severe abnormal fluctuations in stock trading. As of the closing price on September 30, 2025, it was 41.9 yuan/share, with a price-to-earnings ratio of 59.17 times. The latest static price-to-earnings ratio for the general equipment manufacturing industry is 44.33 times. Shareholders holding more than 5%, Nanjing Baolifeng Venture Capital Partnership, have cumulatively reduced their holdings by 2,123,515 shares, accounting for 2.96% of the company's total share capital. The company's operations are normal, and there is no significant undisclosed information that should be disclosed"
datetime: "2025-09-30T10:06:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259498349.md)
  - [en](https://longbridge.com/en/news/259498349.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259498349.md)
generator: "portal-rs"
---

# CIGU TECHNOLOGY: The cumulative deviation value of the closing drop on the 30th is 70%

CIGU TECHNOLOGY announced that the company's stock price has deviated by a cumulative decline of 70% over the last 30 trading days, triggering severe abnormal fluctuations in stock trading; as of September 30, 2025, the closing price is RMB 41.9 per share, with a price-to-earnings ratio of 59.17 times. The latest static price-to-earnings ratio for the general equipment manufacturing industry is 44.33 times; shareholders holding more than 5%, Nanjing Baolifeng Venture Capital Partnership, have cumulatively reduced their holdings by 2,123,515 shares, accounting for 2.96% of the company's total share capital; the company's operations are normal, and there is no significant undisclosed information that should be disclosed

### Related Stocks

- [688448.CN](https://longbridge.com/en/quote/688448.CN.md)

## Related News & Research

- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDA](https://longbridge.com/en/news/296476562.md)
- [JDC: Record growth in turnover and EBITDA, with strong outlook driven by new regulation and AI](https://longbridge.com/en/news/296247395.md)
- [OCC races to finalize GENIUS Act stablecoin rules by November](https://longbridge.com/en/news/296383830.md)
- [giga! Equips All Eligible MILK Fund Scholars with One-year gigaFLEX+ Plan](https://longbridge.com/en/news/296587727.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**